BioCrea Wins The Epilepsy Innovation Seal of Excellence Award

BioCrea GmbH, the first-in-class CNS drug discovery specialist validated through pharma partnerships, has received the Epilepsy Innovation Seal of Excellence Award from the Epilepsy Foundation (Maryland, US) has presented to BioCrea in recognition of its creation of the new anti-seizure platform, Novel Long Term Effective GABAA PAMs (LT GABAA PAM), to treat refractory epilepsy.

"We are delighted to receive the prestigious SEAL award," said Dr Tom Kronbach, CEO of BioCrea. "This recognition by the Epilepsy Foundation for our work on the LT GABAA PAM platform is highly appreciated. We are impressed that the Foundation's Scientific Advisory Board and Business Advisory Board do see the potential for our platform to deliver efficacious and novel epilepsy treatments which are currently at candidate selection stage. Having successfully delivered novel treatments for partners such as Pfizer, GlaxoSmithKline, Wyeth and Boehringer Ingelheim, we are well placed to further build our portfolio of projects."

The Epilepsy Foundation stated in a letter to BioCrea: "This award is based on the enthusiasm of the Epilepsy Foundation's Scientific Advisory Broad and Business Advisory Board for the present accomplishments and future potential of this new drug platform that we hope will alleviate the suffering of persons with epilepsy."